Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...
Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Can you chip in? This year we’ve reached an extraordinary milestone: 1 trillion web pages preserved on the Wayback Machine. This makes us the largest public repository of internet history ever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback